NCT06921044尚未招募2 期
A Multicenter, Prospective Phase Ⅱ Clinical Study of R-mini-MCOP（Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone） in the Treatment of Elderly, Previously Untreated Diffuse Large B-cell Lymphoma
Xiaohui He0 个研究点目标入组 33 人开始时间: 2025年4月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 33
- 主要终点
- Complete response rate （CRR）
研究概览
简要总结
Research purpose： To evaluate the efficacy and safety of R-mini-MCOP in first-line treatment of primary treatment of diffuse large B-cell lymphoma (DLBCL) in elderly patients Experimental design： Single-arm, multicenter, prospective study
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 80 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 80 years
- •The histopathological diagnosis was diffuse large B-cell lymphoma, and immunohistochemistry was positive for CD20
- •Previously untreated disease
- •Ann Arbor stage I-IV disease
- •According to Lugano2014 criteria, there must be at least one matching evaluable or measurable lesion: lymph node lesion, the length of the measurable lymph node must be greater than 1.5cm; For non-lymph node lesions, the measured extra-nodal lesions should be > 1.0cm in length;
- •ECOG score 0-4(ECOG score 0-2 after pre-treatment and before R-mini-MCOP regimen)
- •Bone marrow function: neutrophil count ≥1.5×109/L, platelet count ≥75×109/L, hemoglobin ≥80g/L (neutrophil count ≥1.0×109/L, platelet count ≥50×109/L, hemoglobin ≥75 g/L in patients with bone marrow involvement);
- •Liver and kidney function: serum creatinine ≤1.5 times the upper limit of normal value; AST and ALT ≤2.5 times the upper limit of normal (≤5 times the upper limit of normal for patients with liver invasion); Total bilirubin ≤1.5 times the upper limit of normal value (≤3 times the upper limit of normal value for patients with liver invasion;
- •Have the swallowing power
- •Life expectancy > 3 months
- •Patients fully understand the study, voluntarily participate and sign an informed consent form (ICF) -
排除标准
- •Previous systemic antitumor therapy (except pre-therapy used before the first cycle of R-CMOP);
- •Metastatic diffuse large B-cell lymphoma；
- •Known central nervous system lymphoma
- •Hypersensitivity to any investigational drug or its ingredients;
- •Uncontrollable systemic diseases (such as advanced infections, uncontrolled hypertension, diabetes, etc.);
- •Hepatitis B and hepatitis C active infection (hepatitis B virus surface antigen positive and hepatitis B virus DNA more than 1x103 copies /mL; More than 1x103 copies /mL of HCV RNA);
- •Human immunodeficiency virus (HIV) infection (HIV antibody positive);
- •Other serious comorbidities, intolerance to this protocol or inappropriate participation in this study (judged by the investigator)
- •Previous or current co-occurrence of other malignancies (other than non-melanoma basal cell carcinoma of the skin that is effectively controlled, breast/cervical carcinoma in situ, and other malignancies that have been effectively controlled without treatment within the past five years);
- •Inability to swallow the drug or any significant removal of the small intestine that may prevent full absorption of the drug;
- •Situations in which other investigators have determined that participation in this study is not appropriate.
研究组 & 干预措施
R-mini-MCOP
Experimental
Rituximab ：375 mg/m2，ivgtt，d0； Mitoxantrone Liposome ： The first dose level: 6mg/m2, ivgtt, d1; The second dose level: 8mg/m2, ivgtt, d1; The third dose level: 10mg/m2, ivgtt, d1; Cyclophosphamide :400 mg/m2，ivgtt，d1； Vincristine :1mg，ivgtt，d1； Prednisone:40 mg/m2，po.，d1-5； Q3W（Every 3 Weeks）
干预措施: R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone (Drug)
结局指标
主要结局
Complete response rate （CRR）
时间窗: At the end of Cycle 2 (each cycle is 21 days)
Complete response rate at the end of induction
次要结局
- Overall Response (CR+PR) Rate （ORR）(At the end of Cycle 2 (each cycle is 21 days))
- Duration of response (DOR)(From the date when criteria for response are met (CR or PR) until the date of progression or relapse. Patients without relapse or progression or death from other causes will be censored at their last assessment date (24 months from response date))
- Progression-free survival (PFS)(Time between the date of enrolment and the date of disease progression, relapse or death from any cause (12,24 months))
- Event Free Survival (EFS)(From the date of enrolment to the date of disease progression, relapse from CR, initiation of subsequent systemic anti-lymphoma therapy after the least 6 cycles of RI-CHOP (each cycle is 21 days), or death whichever occurs first (24, 36 and 48 months))
- Overall Survival (OS)(Time between the date of enrolment and the date of death from any cause (12,24, 36 and 48 months))
研究者
Xiaohui He
Chief physician，Professor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
相似试验
招募中
1 期
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaDiffuse Large B-cell LymphomaNCT06594640Institute of Hematology & Blood Diseases Hospital, China108
招募中
2 期
CMOP±R in the Treatment of Untreated Non-Hodgkin's LymphomaNHLNCT06486337The First Affiliated Hospital of Soochow University197
招募中
1 期
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCLDiffuse Large B-Cell LymphomaNCT06760039Sun Yat-sen University112
终止
2 期
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)Acute Lymphoblastic LeukemiaNCT01685021MorphoSys AG22
招募中
1 期
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.Non-Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)PTCL-NOSAITLHodgkin LymphomaALCLLymphomaNCT06137144AstraZeneca161